Preclinical studies have shown that efbemalenograstim alfa is a stronger activator of G-CSFR, based on faster neutrophil recovery times and the occurrence of less severe neutropenia; however, this has not yet been demonstrated in human clinical trials. The gene discussed is CSF3R; the disease is Decreased total neutrophil count.